Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong buy rating despite FDA uncertainties. Shares rallied ~5% in after-hours ...
The stock is cheap given the company's revenue growth and margins. Hims & Hers strong performance involves much more than just GLP-1 drugs. Hims & Hers once again delivered a blowout quarter with ...
When you think about the benefits of protein, building and maintaining muscle are likely what come to mind. But this powerhouse nutrient has many other benefits as well—from increasing energy ...
Whether you prefer eating meat, tofu or another source, protein is an important part of a well-balanced diet. It's what helps your body perform its most essential tasks, like regulating hormones ...
Direct-to-consumer telehealth company Hims & Hers is defending its sale of compounded glucagon-like peptide agonists, or GLP-1s, even as shortages of the name brand weight loss medications are waning.